Data were “fraudulently obtained” in epilepsy paper, probe finds

brain-research-bulletinA brain research journal has retracted a 2016 study about epilepsy after an institutional investigation determined that some of the data were taken from another published paper.

The retraction notice for the study — which appeared in Brain Research Bulletin — cites an investigation by the scientific integrity committee at Tongji University in Shanghai, China, which concluded the authors had engaged in “unethical publishing behavior.”

Here’s the retraction notice for “Clc-2 knockout attenuated experimental temporal lobe epilepsy in mice by tonic inhibition mediated by GABAA receptors:” Continue reading Data were “fraudulently obtained” in epilepsy paper, probe finds

Coding error sinks cancer study

Authors of a 2016 cancer paper have retracted it after finding an error in one line of code in the program used to calculate some of the results. Reposting as our subscription software appears to be acting up again. Read the whole post here.

Error in one line of code sinks cancer study

journl-of-clinical-oncologyAuthors of a 2016 cancer paper have retracted it after finding an error in one line of code in the program used to calculate some of the results.

Sarah Darby, last author of the now-retracted paper from the University of Oxford, UK, told Retraction Watch that the mistake was made by a doctoral student. When the error was realized, Darby said, she contacted the Journal of Clinical Oncology (JCO), explained the issue, and asked whether they would prefer a retraction or a correction. JCO wanted a retraction, and she complied.

The journal allowed the authors to publish a correspondence article outlining their new results.

Here’s the lengthy retraction notice, published online last month: Continue reading Error in one line of code sinks cancer study

Weekend reads: World’s most prolific peer reviewer; replication backlash carries on; controversial PACE study re-analyzed

booksThe week at Retraction Watch featured news of a fine for a doctor who took part in a controversial fake trial, and a likely unprecedented call for retraction by the U.S. FDA commissioner. Here’s what was happening elsewhere: Continue reading Weekend reads: World’s most prolific peer reviewer; replication backlash carries on; controversial PACE study re-analyzed

BMJ won’t retract controversial dietary guidelines article, says author

bmjThe BMJ is not going to retract a 2015 article criticizing the expert report underlying the U.S. dietary guidelines, despite heavy backlash from readers, according to the author of the article.

As Politico reported today, the publication told journalist Nina Teicholz it wouldn’t retract the article, first published one year ago today.

Teicholz confirmed to us the journal emailed her in April to say the article would not be retracted: Continue reading BMJ won’t retract controversial dietary guidelines article, says author

Authors retract two papers on shock therapy, citing language barriers

the-journal-of-ectAn electroconvulsive therapy (ECT) journal has retracted two 2016 papers after uncovering problems in the data analyses, which the author says were due to language barriers.

Interestingly, two authors of the newly retracted papers — Yu-Tao Xiang from the University of Macau in China and Gabor Ungvari from the University of Western Australia — also recently co-authored another paper on an entirely different topic that has received a lengthy correction. That paper — on the use of organs from executed prisoners in China — raised controversy for allegedly reporting a “sanitized” account of the practice. The correction notice, in the Journal of Medical Ethics, was accompanied by a critics’ rebuttal to the paper.

According to Xiang, the newly retracted papers in The Journal of ECT — which examined the efficacy of ECT in treating schizophrenia — were pulled due to “genuine errors” resulting from differences in language. All the authors agree with the retraction, Xiang noted. 

Xiang told us: Continue reading Authors retract two papers on shock therapy, citing language barriers

Author asks to retract nearly 20-year old paper over figure questions, lack of data

journal-of-biological-chemistryThe last author of a 1999 paper has asked the journal to retract it less than one month after a user raised questions about images on PubPeer.

Yesterday, last author Jim Woodgett posted a note on the site saying the author who generated the figures in question could not find the original data, and since he agreed the images appeared “suspicious,” he had contacted the journal to retract the paper.

Here’s the note from Woodgett, based at Lunenfeld-Tanenbaum
Research Institute at Mount Sinai Hospital in Toronto: Continue reading Author asks to retract nearly 20-year old paper over figure questions, lack of data

Finnish institute finds no evidence to support misconduct in diabetes paper

VTT Research CentreAn investigation at the VTT Technical Research Centre of Finland has found no evidence of misconduct by one of its former researchers in a diabetes paper.

We previously reported on the case after the VTT was accused of cutting corners in a previous investigation into Matej Orešič (now based at the Steno Diabetes Center in Gentofte, Denmark). In 2014, the VTT concluded that there was no evidence of falsification or data tampering on the part of Orešič in the 2008 paper published in the Journal of Experimental Medicine (JEM). The proceedings came into the public domain through a news article published in the Finnish media outlet Helsingin Sanomat in February 2016, which prompted the VTT to reopen the case.

Now, the same people who questioned the previous investigation told us they have doubts about the latest conclusions, noting the probe should not have focused on a single paper, but rather on alleged problems within the plasma and serum metabolomics group, previously led by Orešič.

Orešič sent us this report, which the VTT released on June 15, outlining their decision. The VTT confirmed the legitimacy of the report, which says: Continue reading Finnish institute finds no evidence to support misconduct in diabetes paper

Doctor who participated in fake chocolate study fined for violating code of conduct

Source: AKA
Source: AKA

A German district attorney has fined a doctor who participated in a bogus study showing chocolate helps weight loss, designed to illustrate how shady science can make the news, arguing it was unethical to ask people to participate unknowingly in such a scam.

As soon as the study was published, critics raised questions over whether it was appropriate to include volunteers in a bogus clinical trial, which included giving blood. Recently, a German district attorney for professional conduct of physicians ruled that it was not.

In an anonymized version of a decision from the district attorney – who investigates on possible violations of the physicians’ professional law – he fined the doctor who participated in a bogus study about the health benefits of chocolate 500 Euros for not obtaining proper consent from the people who volunteered to participate, and for not involving an ethics committee. Continue reading Doctor who participated in fake chocolate study fined for violating code of conduct

Amid controversial Sarepta approval decision, FDA head calls for key study retraction

FDAThe head of the U.S. Food and Drug Administration (FDA) has called for the retraction of a study about a drug that the agency itself approved earlier this week, despite senior staff opposing the approval.

On September 19, the FDA okayed eteplirsen to treat Duchenne muscular dystrophy (DMD), a rare genetic disorder that results in muscle degeneration and premature death. Several of its top officials disagreed with the drug’s approval, questioning how beneficial it will be for patients, as Forbes, MedPage Today and others reported.

In a lengthy report Commissioner Robert Califf sent to senior FDA officials on September 16 — that was made public on September 19 — he called for the retraction of a 2013 study published in Annals of Neurology funded by the seller of eteplirsen, which showed beneficial effects of the drug in DMD patients. Califf writes in the report:

Continue reading Amid controversial Sarepta approval decision, FDA head calls for key study retraction